REG - Theracryf PLC - New Manufacturing Process Patent for Ox-1

TheracryfAnnouncement

16/04/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260416:nRSP6260Aa&default-theme=true

RNS Number : 6260A  Theracryf PLC  16 April 2026

 

16 April 2026

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

 

New Manufacturing Process Patent Extends Exclusivity for Lead Asset Ox-1

Additional patent submission provides potential 20-year protection

Strengthens long-term commercial value and partnering potential

 

TheraCryf plc (AIM: TCF), the biotech company developing new medicines for
addiction and other neuropsychiatric disorders, today announces that it has
filed a new process patent covering novel aspects of the manufacturing method
for its lead programme, a selective orexin-1 receptor antagonist (Ox-1) being
developed for addiction.

 

The patent, when granted, will protect for 20 years from filing, potentially
to 2046, extends the commercial exclusivity for the Ox-1 blocker across major
markets, substantially beyond the life of the existing global Composition of
Matter patent. The filing follows recent successful manufacturing optimisation
and scale-up work during which several novel and efficiency-enhancing chemical
process improvements were identified.

 

Process patents provide an additional barrier to generic competition, as
alternative manufacturing routes must be developed to avoid infringement,
which are typically not undertaken by competitors. The filing builds on the
Company's recently announced strengthening of the Ox-1 patent estate across
key global markets and forms part of its broader strategy to establish a
robust intellectual property portfolio as the programme advances towards
completing the data required for clinical readiness later in 2026.

 

Dr Huw Jones, Chief Executive Officer of TheraCryf, commented:

 

"This new process patent submission further strengthens the intellectual
property protection surrounding our lead asset and has the potential to extend
its commercial exclusivity very substantially.

 

As TheraCryf progresses swiftly towards clinical development, expanding our
broad and defensible patent portfolio is central to maximising the long-term
commercial value of the programme and its attractiveness to potential
partners."

 

-Ends-

 

Enquiries

 

 TheraCryf plc                                      +44 (0)1625 315 090

 Dr Huw Jones, CEO                                  enquiries@theracryf.com

 Toni Hänninen, CFO

 Dr Helen Kuhlman, COO

 Singer Capital Markets (NOMAD & Joint Broker)      +44 (0)20 7496 3000
 Phil Davies / Patrick Weaver

 Turner Pope Investments (Joint Broker)             +44 (0)20 3657 0050

 Guy McDougall / Andy Thacker

 Northstar Communications (Investor Relations)      +44 (0)113 730 3896

 Sarah Hollins                                      sarah@northstarcommunications.co.uk
                                                    (mailto:sarah@northstarcommunications.co.uk)

 

About TheraCryf

 

TheraCryf plc is a biotechnology company developing new medicines for
addiction and other neuropsychiatric disorders, areas of significant unmet
medical need within central nervous system (CNS) disorders.

 

The Group's lead programme is a novel, best-in-class orexin-1 receptor
antagonist being developed as a potential treatment for addiction, including
binge eating, alcohol and other substance use disorders.

The programme has already been heavily de-risked for both safety/tolerability
and efficacy in previous testing and is fully funded through final
pre-clinical trials to clinical readiness, with regulatory submissions for
first in man studies targeted for 2026.

 

TheraCryf also has a dopamine transporter (DAT) modulator programme addressing
fatigue of brain origin, including fatigue associated with multiple sclerosis,
chemotherapy and narcolepsy. The Group also has a legacy, grant-funded,
oncology programme in glioblastoma with SFX-01.

 

The Group operates a capital-light, virtual development model advancing
programmes to early clinical or proof-of-concept stage before partnering with
larger pharmaceutical or biotechnology companies.

TheraCryf's headquarters and registered office are at Alderley Park, Cheshire.

 

For further information, visit: https://theracryf.com (https://theracryf.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RESFLFLVSRIELIR



            Copyright 2019 Regulatory News Service, all rights reserved